Related Experiment Video

Updated: Nov 7, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

Alice Indini1, Olga Nigro2, Csongor György Lengyel3

  • 1Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy.

Cancers
|April 30, 2021
PubMed

Insights

Platinum-resistant ovarian cancer (OC) has poor prognosis. This review explores OC immunobiology and immunotherapy combinations to improve treatment outcomes for this challenging disease.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Platinum-resistant ovarian cancer (OC) presents limited therapeutic options and a poor prognosis.
  • Molecular mechanisms of platinum resistance in OC may overlap with tumor immunogenicity.
  • Current immunotherapy approaches, like single-agent checkpoint inhibitors, have shown disappointing results in OC.

Purpose of the Study:

  • To review the immunobiology of ovarian cancer and its potential for immunotherapy.
  • To discuss existing clinical trial data and biomarkers for immunotherapy in platinum-resistant OC.
  • To provide an overview of future drug development strategies for immunotherapy in OC.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of immunobiology in ovarian cancer.
  • Evaluation of clinical trial outcomes and biomarker data.

Main Results:

  • Exploration of combination immunotherapy strategies (with chemotherapy, anti-angiogenics, PARP inhibitors) is ongoing.
  • The precise role of immunotherapy in platinum-resistant OC treatment is still undefined.
  • Biomarkers and novel drug development are crucial for advancing immunotherapy.

Conclusions:

  • Further research into OC immunobiology is needed to optimize immunotherapy.
  • Combination strategies and biomarker identification are key to improving outcomes in platinum-resistant OC.
  • Future drug development should focus on novel immunotherapy approaches for ovarian cancer.
Keywords:
immune checkpoint inhibitorsimmunotherapynew drugsovarian cancerplatinum-resistance

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.5K
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
807
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K